Vallon Pharmaceuticals, Inc. (VLON): Price and Financial Metrics
GET POWR RATINGS... FREE!
VLON Stock Price Chart Interactive Chart >
VLON Price/Volume Stats
| Current price | $0.27 | 52-week high | $2.78 |
| Prev. close | $0.27 | 52-week low | $0.21 |
| Day low | $0.26 | Volume | 181,486 |
| Day high | $0.28 | Avg. volume | 470,749 |
| 50-day MA | $0.28 | Dividend yield | N/A |
| 200-day MA | $0.48 | Market Cap | 3.41M |
Vallon Pharmaceuticals, Inc. (VLON) Company Bio
Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of prescription drugs for central nervous system disorders. The company develops abuse-deterrent amphetamine immediate-release, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder and narcolepsy. It also develops ADMIR, an abuse deterrent formulation of Ritalin. The company was incorporated in 2018 and is based in Philadelphia, Pennsylvania.
Latest VLON News From Around the Web
Below are the latest news stories about VALLON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate VLON as an investment opportunity.
Vallon Pharmaceuticals Reports Third Quarter 2022 Financial ResultsPHILADELPHIA, PA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today reported its financial results for the quarter ended September 30, 2022. |
Vallon Pharmaceuticals reports Q3 resultsVallon Pharmaceuticals press release (VLON): Q3 Net loss was $1M for the quarter ended September 30, 2022.As of September 30, 2022, the company had cash, cash equivalents and… |
Vallon Pharmaceuticals Inc.’s Stock Gains 9.59%, But It May Still Be Worth Investing In.The trading price of Vallon Pharmaceuticals Inc. (NASDAQ:VLON) floating higher at last check on Wednesday, October 05, closing at $0.33, 9.59% higher than its previous close. Traders who pay close attention to intraday price movement should know that it has been fluctuating between $0.26 and $0.34. In examining the 52-week price action we see that … Vallon Pharmaceuticals Inc.’s Stock Gains 9.59%, But It May Still Be Worth Investing In. Read More » |
Vallon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate UpdatePHILADELPHIA, PA, July 28, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today reported its financial results for the quarter ended June 30, 2022 and provided a corporate update. |
Vallon Pharmaceuticals reports Q2 resultsVallon Pharmaceuticals press release (VLON): Q2 net income was -$1.8M.Shares +2.36% PM. |
VLON Price Returns
| 1-mo | -6.90% |
| 3-mo | 4.53% |
| 6-mo | -35.08% |
| 1-year | -83.40% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -6.90% |
| 2022 | -85.45% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...